Nexalin Technology (NXL) Capital Expenditures (2026)
Nexalin Technology's quarterly Capital Expenditures came in at $49276.0 in Q1 2026.
Nexalin Technology has reported Capital Expenditures for 1 years, with the latest figure at $49276.0 in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 399.00 Mn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 166.00 Mn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 444.00 Mn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 177.00 Mn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 64.90 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -85.46 Mn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 76.60 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 86.00 Mn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 90.20 Mn |
| 10 | Nexalin Technology | 11.19 Mn | 8.48 Mn | 13,133.00 | 49,276.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49,276.00 |
| Mar 31, 2026 | 49,276.00 |